Publications

H-FACTOR = 74, Citations 33,103

  1. Latham S, Bartley PA, Budgen B, Ross DM, E, Hughes E, Branford S, White DL,Hughes TP, Morley A. BCR-ABL1 Expression and Decision on Treatment in Chronic Myeloid Leukemia. Accepted Journal of Clinical Pathology Jan 2016
  2. Nievergall E, Reynolds J, Kok C, Watkins D, Biondo M, Busfield SJ, Vairo G, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL. Predictive value of TGF- α and IL-6 plasma levels to identify CML patients that fail to achieve an early molecular response or progress in the first year of therapy. 15-LEU-1289R Accepted Leukemia January 2016
  3. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DQ, Issaragrisil S, le Coutre P, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantajian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid Leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Accepted Leukemia Jan 2016
  4. Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison B, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. BLOOD/2016/666214
  5. Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, Yong A. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. BLOOD 2015 Dec 126 (25) 2720-2723.
  6. le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. LeukemiaDec 2015.
  7. Watkins DB, Hughes TP, White DL. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. 2015 29;10 1960-1969.
  8. White DL, Hughes TP. Living with CML: is death no longer the end (point)? BLOOD July 2015 126(1) 2-4
  9. Ong J, Yeung DT, Filshie R, Hughes TP, Nandurkar H. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. International Journal of Hematology 2015 Vol 1, 1-4 CIT 1
  10. Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D'Rozario j, Rooney K, Lynch K, Bradstock K. An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Mar2015 Leukemia & Lymphoma 56:3 630-638
  11. Hughes TP, Saglio G, Quintas-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley B, Ukropec J, Hochhaus A. BCR-ABL1 mutuation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia Sept 2015 29(9) 1832-1838
  12. Lu L, Saunders V, Leclercq T, Hughes TP, White D. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukaemia,13 Feb 20151038/leu.2015.35CIT 1
  13. Yeung D, Osborn MP, White DL, Branford S, Braley J, Herschtal, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer A, Filshie R, Arthur C, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP.TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. BLOOD Feb 2015; 125: 915 - 923. CIT 10
  14. Olshen A, Tang M, Cortes J, MGonen M, Hughes TP, Branford S, Quintas-Cardama A, Michor F. Dynamics of Chronic Myeloid Leukemia response to Dasatinib, Nilotinib, and High-Dose Imatinib. Haemotologica November 2014 99: 1701-1709 CIT 3
  15. Bartley PA, Latham S, Budgen B, Ross DM, Hughes E, Branford S, White DL, Hughes TP, Morley A. A DNA-qPCR method suitable for routine monitoring of low levels of minimal residual disease inchronic myeloid leukemia. Journal of Molecular Diagnostics Oct 201417(2) 185-192 CIT 2
  16. Roberts KG, Li Y,Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11;371(11):1005-15. CIT 118
  17. Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes TP, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014 29(1) 76-85 CIT 4
  18. Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mulligan CG, Hughes TP, White DL. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia Sep 2014 Leu.2014.256 CIT 3
  19. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood. 2014 Jul 3;124(1):153-5CIT 8
  20. Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014 Jul 31;124(5):729-36. CIT 9
  21. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014 Jul 24;124(4):511-8 CIT 39
  22. Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, White DL. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia May 2014 | doi:10.1038/leu.2014.156 CIT 5
  23. Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol.2014 Jul;166(1):3-11 CIT 16
  24. Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F.Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol. 2014 May;99(5):616-24
  25. Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul;99(7):1204-11 CIT 1
  26. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014 Jul;55(7):1451-62 CIT 7
  27. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014Feb 27;123(9):1353-60 CIT 61
  28. Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF,Hughes TP, White DL, Hiwase DK. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014Feb 20;123(8):1218-28. CIT 19
  29. Eadie LN, Hughes TP, White DL. Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib. Clin Pharmacol Ther.2014;95(3):294-306. CIT 17
  30. Kok CH, Leclercq T, Watkins DB, Saunders V, Wang J, Hughes TP, White DL. Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia. 2014;28(3):702-705.
  31. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr;27(4): 907-913 CIT 20
  32. White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes TP, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem. 2013 Jun;59(6): 938-948 CIT 21
  33. Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes TP, Parker MW, Lopez AF. Signalling by the βc family of cytokines. Cytokine Growth Factor Rev. 2013 Jun;24(3):189-201 CIT 14
  34. Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer. 2013 Apr 2;13(1):173. CIT 6
  35. Ross DM, O'Hely M, Bartley PA, Dang P, Score J, Goyne JM, Sobrinho-Simoes M, Cross NC, Melo JV, Speed TP, Hughes TP, Morley AA. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia. 2013Oct;27(10): 2105-2107. CIT 5
  36. Experts in Chronic Myeloid Leukemia, a group of more than 100 experts in chronic myeloid leukemia (CML). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 May 30;121(22): 4439-4442.
  37. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013 Jul 25;122(4): 515-522 CIT 163
  38. Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, Branford S. BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013 Sep 17;109(6): 1593-1598. CIT 8
  39. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood.2013 Aug 8;122(6): 872-884 CIT 501
  40. Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L,Hughes TP, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol. 2013Dec;163(5): 674-676. CIT 1
  41. White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. 2013 Leukemia 27 (5) 1201-4 CIT 4
  42. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov: 369(19):1783-1796 CIT 241
  43. Hochhaus A, Saglio G, Larson RA, Kim D-W, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP.Nilotinib is associated with a reduced incidence of BCR-ABL mutations vesus imatinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase. 2013 Blood 121(18):3703-8 CIT 34
  44. Branford S, Yeung D, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J. Hughes TP. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1 the criteria for imatinib discontinuation in patients with CML. 2013 Blood 121(9):3818-3824 CIT 52
  45. Kok CH, Watkins DB, Leclercq T, D’Andrea R, Hughes TP, White DL. Low GFI1 expression in white blood cells of Cp-CML patients at diagnosis is strongly associated with subsequent blastic transformation. 2013 Leukaemia Jun;27(6):1427-1430 CIT 8
  46. Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino ACW, Pitson S, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. 2013 PLOS Biology 11(3) e1001515 CIT 8
  47. Watkins DB, Hughes TP, White DL, D’Andrea RJ. NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. Leukemia. 2013 Feb;27(2):489-90 CIT 7
  48. Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino ACW. Prospective histomorphometric and DXA evaluation of bone remodelling in imatinib-treated CML patients: evidence for site-specific skeletal effects. 2012 J Clin Endocrinol Metab 98:67-76IF 5.9 CIT 6
  49. Hiwase DK, Saunders VA, Nievergall E, Ross DM, White DL, Hughes TP. Dasatinib targets chronic myeloid leukaemia-CD34+ progenitors as effectively as it targets mature cells. 2012 Haematologica 98(6):896-900 IF 6.4 CIT 8
  50. Cortes J, Goldman JM, Hughes TP. Current issues in chronic myeloid leukaemia: monitoring, resistance and functional cure. 2012 Journal of the National Comprehensive Cancer Network. 10(3): 1-20 IF 4.4 CIT 34
  51. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A and for the SAKK and the German CML study Group. Early molecular and cytogenetic response is predictive for long term progression-free and overall survival in chronic myeloid leukaemia.2012Leukemia 26(9)2096-2102 CIT 201
  52. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase: ENESTnd 3 year follow up. 2012 Leukemia 26(10):2197-2203 CIT 242
  53. Hiwase DK, Hughes TP. Sudden blast crisis in chronic myeloid leukaemia treated with tyrosine kinase inhibitors. 2012 Leukaemia Lymphoma 53(7): 1251-2 CIT 1
  54. Eadie LN, Saunders VA, Hughes TP, White DL. The degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. 2012 Leukaemia Lymphoma 54(3):569-578 CIT 8
  55. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F,Hughes TP, White DL, Radich J, Kim D-W, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G. Association between imatinib transporters and metabolising enzymes genotype and response in newly diagnosed chronic myeloid leukaemia patients receiving imatinib therapy.2012 Hematologica 98(2):193-200 IF 6.4 CIT 37
  56. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukaemia in chronic phase: 48 month follow up results of a phase II study. 2012 Leukemia 26(5):959-962 CIT 76
  57. Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Muller MC. Initial molecular response at 3 months may predict both responses and event-free survival at 24 months in imatinib-resistant or intolerant patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (CML-CP) treated with Nilotinib. 2012 J Clin Oncol 30:4323-4329t CIT 46
  58. Yin Oq, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, ochhh Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukaemia. 2012 Cancer Chemother Pharmacol 70(2):345-350 CIT 8
  59. Schafranek L, Leclercq TM, White DL, Hughes TP. Clarithrom ycin enhances dasatinib-induced cell death in CML cells, by inhibition of late stage autophagy.2012 Leukaemia Lymphoma 54(1):198-201 CIT 23
  60. White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G,Hughes TP. Chronic phase chronic myeloid leukaemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard –dose imatinib. 2012Haematologica 97(6): 907-914 CIT 34
  61. Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D’Andrea RJ, White DL. Contrasting effects of dictofenac and ibuprofen on active imatinib uptake into leukaemic cells. 2012 British Journal of Cancer 106:1766-1771 CIT 1
  62. Blake S, Lyons AB, Hughes TP. Drug interaction studies evaluating T cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A 2012 Experimental Haematology 40(8):612-621 CIT 8
  63. Larson RA, Yin OQP, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Dermirhan E, Hughes TP, Kantarijian, le Coutre P. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukaemia in chronic phase. 2012 Eur J Clinical Pharma 68(5):723-733 IF 2.8 CIT 32
  64. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second line kinase inhibitors in chronic myeloid leukaemia patients with multiple low level mutations, irrespective of their resistance profile. 2012 Blood 119:2234-2238 CIT 29
  65. Yeung D, Hughes TP. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. 2012 Critical Reviews in Oncogenesis 17(1) 17-30 IF 1.8 CIT 23
  66. Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes, M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. 2012Haematologica 97(5) 731-738 IF 6.4 CIT 34
  67. Branford S, Yeung DT, Prime JA, Choi S-Y, Bang J-H, Park JE, Kim D-W, Ross DM,Hughes TP. BCR-ABL1 doubling-times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold-rise: implications for monitoring and management. 2012 Blood 119(18)4264-4271 CIT 19
  68. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MR, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wikto-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA. Rac2ndash; mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukaemia stem cells and primitive progenitors. 2012 Blood 119(18)4253-4263 CIT 60
  69. White DL, Hughes TP. Classification of CML patients based on BCR-ABL transcript level at 3 months fails to identify patients with low OCT-1 activity destined to have poor imatinib response. 2012 Journal of Clinical Oncology. 30(10)1144-1145 CIT 13
  70. Hercus T, Broughton S, Ekert H, Ramshaw M, Grimbaldeston M, Perugini M, Woodcock J, Thomas D, Pitson S, Hughes TP, D’Andrea R, Parker M, Lopez A. The GM-CSF receptor family: mechanism of activation and implications for disease.2011 Growth Factors 30(2):63-75 CIT 23
  71. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukaemia: implications and management strategies. 2011 Cancer 118(5):1181-91 CIT 13
  72. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukaemia response to long-term targeted therapy reveal treatment effects of leukaemic stem cells. Blood2011 118:1622-1631 CIT 43
  73. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP. Hochhaus A. BCR-ABL transcripts dynamics support the hypothesis that leukaemic stem cells are reduced during imatinib treatment. Cancer Research2011 17(21): 1-10 CIT 5
  74. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukaemia. Blood 2011 118(13):3634-3644 CIT 25
  75. Kantarjian HM, Hochhaus A, Saglio G, Souza CD, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24 month minimum follow up of the phase-3 randomised ENESTnd trial. Lancet Oncology 2011 12(9):841-51CIT 305
  76. Parker W, Prime J, Ho M, Irwin DL, Scott H, Hughes TP, Branford S. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukaemia after imatinib resistance is predictive of outcome during subsequent therapy. 2011Journal of Clinical Oncology 29(32)4250-4259 CIT 54
  77. Tang C, Schafranek L, WatkinsDB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tyrosine kinase inhibitor resistance in chronic myeloid leukaemia cell lines: Investigating resistance pathways. 2011 Leukaemia Lymphoma 52(11)2139-2147CIT 26
  78. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. 2011 Current Haematology Malignancy Reports 6(2): 88-95 CIT 5
  79. Engler JR, Hughes TP, White DL. OCT-1 as a determinant of reponse to antileukemic treatment. 2011 Clin Pharmacol Ther 89(4):608-11 CIT 11
  80. Branford S, Hughes TP Mutational analysis in chronic myeloid leukaemia: when and what to do? Current Opinion in Hematology (-) 2011 18:111-116 CIT 23
  81. Cortes J, Hochhaus A, Hughes TP, Kantarjian H. Front line salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukaemia. J Clin Oncol (A*) 2011 29:524-531 CIT 64
  82. Kantarijian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Shou Y, Gallagenr NJ, Blakesley, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukaemia in chronic phase after imatinib resistance or intolerance: 24 month follow up results. Blood (A*) 2011117(4):1141-1145 CIT 253
  83. Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? 2011 Leukemia (A*) 25(2):193-200 CIT 12
  84. Engler J, Zannettino ACW, Bailey CG, Rasko JEJ, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica (B) 2011 96(2):213-220 CIT 31
  85. White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT-1 activity measurement provides a superior imatinib response predictor that screening for single-nucleotide polymorphisms of OCT-1. Leukemia (A*) 2010 24(11):1962-1965 CIT 31
  86. Engler J, Frede A, Saunders V, Zannettino ACW, White DL, Hughes TP. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake into their CD34+ cells. Blood (A*) 2010 116:2776-2778 CIT 18
  87. Ross DM, Branford S, Seymour JF, Schwarer AP, Aruthur A, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills A K, Grigg AP, Melo J, Hughes TP. Patients with chronic myeloid leukaemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukaemia by DNA PCR. Leukemia (A*) 2010 24 1719-1724 CIT 161
  88. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda J, Foroni L, Druker B, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP. Long term prognostic significance of early molecular response to imatinib in new diagnosed chronic myeloid leukaemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood (A*) 2010116:3758-3765 CIT 342
  89. Fraser C, Brown M, Diener K, Guerin L, Hughes TP, Lousberg ER, Hayball JD. Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biology & Therapy (A) 2010 10(7): 715-727 CIT 9
  90. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S,Hughes TP, Morley AA. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Hematol (B) 2010 32(6 Pt1):222-228 Cit 30
  91. Eadie L, Hughes TP, White DL. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia (A*) 2010 24(4)855-7CIT 13
  92. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW,Hughes TP. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukaemia treated with imatinib. J Clin Oncol (A*) 2010 28:2761-2767 CIT 139
  93. Saglio G, Kim D-W, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM the ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N. Engl J Med (A*) 2010 362:2251-2259CIT 1046
  94. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW. Plasma adiponectin levels are markedly elevated in Imatinib-treated Chronic Myeloid Leukaemia (CML patients): A mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocinol Metab.(A*) 2010 95:3763-3767 CIT 31
  95. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy 2010 Leukemia (A*) 24: 658-660; CIT 22
  96. Osborn M, Hughes TP. Managing imatinib resistance in chronic myeloid leukaemia.2010 Current Opinions in Hematology (-) 17:97-103 CIT 7
  97. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D-W, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III randomized open label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukaemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. 2010 Journal of Clinical Oncology (A*) 28(3):424-430. CIT 220
  98. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D’Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP. Blocking cytokine signalling along with intense BCR-ABL kinase inhibition induces apoptosis in primary CML progenitors. 2010 Leukemia (A*) 24(4) 771-8 CIT 43
  99. Branford S, Hughes TP. Practical considerations for monitoring patients with chronic myeloid leukaemia 2010 Seminars in Hematology (A) 47(4): 327-334 CIT 14
  100. Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP, White DL. Chronic myeloid leukaemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. 2010 Leukemia (A*) 24(4): 765-70 CIT 53
  101. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW. Dysregulation of bone remodelling by imatinib mesylate. 2010 Blood (A*) 115:766-774 CIT 75
  102. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo. 2009 Experimental Haematology (A) 37(2):256-265 CIT 21
  103. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener K, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. 2009 Exp Hematol (A) 37(12):1435-44 CIT 23
  104. Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes TP,Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic phase chronic myeloid leukaemia resistant to imatinib at a dose of 400 to 800 milligrams daily: two year follow up of a randomized phase 2 study (START-R).2009 Cancer (A) 115(18): 4136-4147 CIT 190
  105. Hughes TP, Branford S. Measuring minimal residual disease in chronic myeloid leukaemia: fluorescence in-situ hybridization and polymerase chain reaction. 2009Clinical Lymphoma & Myeloma (B) 9:(3):266-271 CIT 7
  106. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukaemia patients after imatinib failure – does the BCR-ABL mutation status really matter. 2009 BLOOD (A*) 114:5426-5435CIT 152
  107. Ross DM. Branford S, Melo JV, Hughes TP Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin (letter) 2009 Leukemia (A*) 23:819-820 IF 8.3 CIT 2
  108. Ross DM, Schfranek L, Hughes TP, Nicola M, Branford S, Score J. Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification (letter). 2009 Cancer Genet Cytogenet (B) 189(2): 138-9 CIT 2
  109. Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes TP, Holyoake TL. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patiens who have achieved a complete cytogenetic response (letter). 2009 Leukemia (A*) 23(6): 1199-1201CIT 37
  110. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger F, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes TP, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. Chronic myeloid leukaemia. An update of concepts and management recommendations of European LeukemiaNet. 2009 Journal of Clinical Oncology (A*) 27:6041-51 CIT 1050
  111. Muller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hocchaus A. Dasatinib treatment of chronic phase chronic myeloid leukaemia: analysis of responses according to pre-existing BCR-ABL mutations. 2009 Blood (A*) 114:24 4944-4953CIT 212
  112. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann, Hughes TP, Larson RA, IRIS Investigators. Six-year follow up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia. 2009 Leukemia (A*) 23(6): 1054-61 CIT 684
  113. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. 2009 Current Hematologic Malignancy Reports (-) 4:59-65
  114. Hochhaus A, Muller M, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A. Hughes TP. Dasatinib-associated major molecular responses in patients with chronic myeloid leukaemia in chronic phase following imatinib failure: response dynamics and predictive value. 2009 Leukemia (A*) 23(9): 1628-33 CIT 46
  115. Hughes TP, Saglio G, Branford S, Soverini S, Kim D-W, Muller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukaemia in chronic phase. 2009 Journal of Clinical Oncology (A*) 27:(25) 4204-10 CIT 244
  116. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, Zannettino ACW. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009/5/1 23(5) 994-997 CIT 43
  117. Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP. Short term intense BCR-ABL kinase inhibition with Nilotinib is adequate to trigger cell death in BCR-ABL+ cells. 2009 Leukaemia (A*) 23:1205-1206 CIT 6
  118. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, Zannettino ACW. Imatinib mesylate causes growth plate closure in-vivo. 2009 Leukemia (A*) 23(11): 2155-2159 CIT 28
  119. Viswanathan S, Powers JT, Einhorn W, Hoshida Yujin, Ng T, Toffanin S, O’Sullivan M, Lu J, Philips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 enhances tumorigenesis and is associated with advanced human malignancies. 2009 Nature Genetics (A*) 41(7): 843-8 CIT 448
  120. Hughes TP, Hochhaus A. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. 2009 Seminars in Hematology (A) 46(2) Supp 3:S11-S15 CIT 1
  121. Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med (-) 2008 13:3 CIT O
  122. Apperley J, Cortes JE, Dong-Wook K, Roy L, Roboz GJ, Rosti G, Bullorsky E, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Hyeoung-Joon K, Sillaber C, Hughes TP, Erben P, Van Tornout JMA, Stone RM. Dasatinib in the treatment of chronic myeloid leukaemia in accelerated phase after imatinib failure: The Start A trial. 2009 Journal of Clinical Oncology (A*) 27: 3472-3479 CIT 147
  123. Khoury HJ, Guilhot F, Hughes TP, Kim D-W, Cortes J. Dasatinib treatment for Philadelphia chromosome-positive leukaemias: practical considerations. 2008Cancer (A) 115(7):1381-94 CIT 43
  124. Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughai T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM. BCR-ABL1-positive CML and BCR-ABL1- negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia (A*) 2008 112:3965-3973 CIT 131
  125. Hughes TP, Branford S White DL, Reynolds J, Koelmeyer, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowling P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A on behalf of the Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day. 2008 Blood (A*) 112(10):3965-3973 CIT 113
  126. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes TP, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukaemia. 2008 Semin Oncol (A) 35(Supp1):S1-17; quiz S18-20. CIT 10
  127. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM,Hughes TP. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. 2008 Blood (A*) 112:3330-3338 CIT 248
  128. Hui CH, Sia H, Mangos H, Horvath N, Lee H, Lewis I, Hughes TP, To LB, Bardy P. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients. 2008 Bone Marrow Transplantation (B) 41:409-410 CIT 3
  129. Ross D, Hughes TP. How complete is ‘complete’ molecular response in imatinib-treated CML? (invited commentary) 2008 Leukemia and Lymphoma (B) 49(7)1230-1.. CIT 2
  130. Ross D, Watkins D, Hughes TP, Branford S. Reverse transcription with a random pentadecamen primer increases the detection limit of quantitative PCR for BCR-ABL in chronic myeloid leukaemia: implications for defining the sensitivity of minimal residual disease. 2008 Clinical Chemistry (B) 54:1568-1571 CIT 13
  131. Ross D, Hughes TP. Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. 2008 Pathology (B) 40:231-246CIT 16
  132. Fitter S, Dewar A, Kosatakis P, To LB, Hughes TP, Roberts M, Lynch K, Vernon-Roberts B, Zannettino ACW. Long term imatinib therapy promotes bone formation in CML patients. 2008 Blood (A*) 111:5 2538-2547 CIT 126
  133. Hiwase D, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White D. Dasatinib cellular uptake and efflux in chronic myeloid leukaemia. Cells: Therapeutic Implications. 2008 Cancer Therapy: Clinical (A) 14(12) 3881-3888 CIT 147
  134. Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukaemia in chronic phase with resistance or intolerance to imatinib. 2008 Leukaemia (A*) 22:1200-1206 CIT 334
  135. Shah N, Kantarijian M, Dong-Wook K, Rea D, Dorlhiac-Llacer, Milone J, Vela-Ojeda J, Silver R, Khoury J, Charbonnier A, Khoroshko N, Paquette R, Deninger M, Collins R, Otero I, Hughes TP, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with Dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and intolerant-chronic-phase chronic myeloid leukaemia. 2008 Journal of Clinical Oncology (A*) 26: 3204-3212 CIT 394
  136. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui C_H, Relling MV, Shurtleleff SA, Downing JR. BCR-ABL1 lymphoblastic leukaemia is characterised by the deletion of Ikaros. 2008 Nature (A*) 453(7191):110-4CIT 601
  137. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The SRC/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. 2008 Clin Immunol (C) 127(3):330-9. CIT 59
  138. Le Coutre P, Ottmann O, Giles F, Dong-Wook K, Coretes J, Gattermann N, Apperley J, Larson R, Abruzzese E, O’Brien S, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Yok-Lam K, Baccarani M, Hughes TP, Martinelli G, Radich G, Zheng M, Shou Y, Kantarijian H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or intolerant accelerated phase chronic myelogenous leukaemia. 2008 Blood (A*) 111:1834-1839 CIT 284
  139. Blake SJ, Lyons AB, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitrokiller cell cytotoxicity (letter). 2008 Blood (A*) 111:8 4415-4416 CIT 57
  140. Cross NC, Hughes TP, Hochhaus A, Goldman JM. International standardisation of quantitative real-time RT-PCR for BCR-ABL (letter). 2007 Leukemia Research (B) 32:505-506 CIT 2
  141. Hughes TP. Is drug treatment superior to allografting as first line therapy in chronic myeloid leukaemia. 2007 Nature Clinical Practice Oncology (C) 5(1)14-15CIT 1
  142. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes TP. BCR-ABL mRNA levels continue to decline in patients with chronic phase chronic myeloid leukaemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. 2007 Clinical Cancer Research (A*) 13:780 CIT 41
  143. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs (letter). 2007 Blood (A*) 109:3609-10 CIT 29
  144. White DL, Saunders V, Dang P, Engler J, Venable A, Zrim S, Zannettino A, Lynch K, Manley P, Hughes TP. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. 2007 Blood (A*) 110:12:4064-4072 CIT 271
  145. White DL, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB,Hughes TP. Measurement of in-vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in CML. 2007 Journal of Clinical Oncology (A*) 25(28) 4445-4451. CIT 18
  146. Branford S, Hughes TP, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K.. Efficacy and safety of imatinib in patients with chronic myeloid leukaemia and complete or near-complete cytogenetic response to interferon-alpha. 2007 Cancer (A) 110(4):801-8. CIT 9
  147. Hughes TP, Branford S. Ph++ ALL: resistance seeds sown early. Inside Blood Capsule. 2007 Blood (A*) 110 (2): 472
  148. Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. 2007 Journal of Clinical Investigation (A*) 117(9) 2562-2569CIT 314
  149. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J,Hughes TP, Countouriotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukaemia after failure of first-line imatinib: a randomised phase-II trial. 2007 Blood (A*) 10:1182 CIT 402
  150. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukaemia after failure of imatinib therapy. 2007 Blood (A*) 109:2303-2309. CIT 601
  151. Hughes TP, Branford S, Goldman J. Response: reliability of PCR for BCR-ABL transcripts. 2007 Blood (A*) 109:2263-2264.
  152. Druker B, Guilhot F, O’Brien S, Gathman I, Kantasrjian H, Gattermann N, Deininger M, Silver R, Goldman J, Stone R, Cervantes F, Hochhaus A, Powell B, Gabrilove J, Rousselot P, Reiffers J, Cornelissen J, Hughes TP, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen J, Radich J, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson R. Five-year follow up of patients receiving Imatinib for chronic myeloid leukaemia. 2006 New England Journal of Medicine (A*) 355:2407-17. CIT 2643
  153. Luke C, Nguyen AM, To LB, Seshadri R, Hughes TP, Bardy P, Colbeck M, Buranyi-Trevarton D, McMellon M, Roder D. Myeloid leukaemia and treatment and survival – the South Australian Experience 1977 – 2002. 2006 Asian Pacific J Cancer Prev (-) (7): 227-233
  154. Branford S, Cross NC, Hochhaus A, Radich J, Saglio, Kaeda J, Goldman J, Hughes T.Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. 2006Leukaemia (A*) 20(11):1925-30. CIT 147
  155. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M,Hughes TP, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European Leukaemia Net. 2006 Blood (A*) 108(6):1809-1820. CIT 1257
  156. Grigg A, Hughes TP. Role of allogeneic stem cell transplantation for adult chronic myeloid leukaemia in the imatinib era. 2006 Biol Blood Marrow Transplant (A) 12(8):795-807. CIT 29
  157. Hui C-H, Hughes TP. Autologous stem cell collection and autograft for patients with chronic myeloid leukaemia in the era of ABL kinase inhibitors: back to the bench. 2006 Leukaemia and Lymphoma (B) 47(9):1721-3 CIT 1
  158. Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – Review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. 2006 Blood (A*) 108(1):28-37 CIT 931
  159. White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. 2006 Blood (A*) 108(2):697-704CIT 391
  160. Ross DM, Branford S, Moore S, Hughes TP Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. 2006 Leukemia (A*) . 20(4):664-70 CIT 76
  161. Dewar AL, Farrugia AN, Condina MR, To LB, Hughes TP, Vernon-Roberts B, Zannettino ACW. Imatinib as a potential anti-resorptive therapy for bone disease.2006 Blood (A*) 107(11):4334-4337 CIT 68
  162. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. 2006 Blood Reviews (A) 20, 29-41CIT 140
  163. Michor F, Hughes T, Iwasa Y, Branford S, Shah N, Sawyers C, Nowak A. Dynamics of chronic myeloid leukaemia. 2005 Nature (A*) 435(7046):1267-70 June 30 CIT 630
  164. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T. In-vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in de-novo CML patients. 2005 Blood (A*) 106(7)2520-2526CIT 47
  165. Dewar A, Zannettino ACW, Hughes TP, Lyons AB. Inhibition of c-fms by Imatinib – Expanding the spectrum of treatment. 2005 Cell Cycle (-) 4(7):38-40 CIT 27
  166. Dewar A, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. 2005 Immunol Cell Biol (B) 83(1)48-56CIT 21
  167. Dewar A, Cambareri A, Zannettino ACW, Miller B, Doherty K, Hughes TP, Lyons B. Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib.2005 Blood 15:105(8):3127-32 CIT 127
  168. Mollee P, Arthur C, Hughes TP, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM. Interferon-a-2B and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. 2004 Annals of Oncology 15(12):1810-1815 CIT 2
  169. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour J, Durrant S, Browett P, Schwarer A, Arthur C, Catalano J, Leahy M, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes TP. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. 2004 Blood 104:9 CIT 122
  170. Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, Schwarer A, Szer J, Tait B, To LB, Bardy P. Non-HLA immunogenetic polymorphisms and the risk of complications following allogeneic haemopoietic stem cell transplantation. 2004Transplantation 27(4):587-596. CIT 33
  171. Szer J, Durrant S, Schwarer AP, Bradstock KF, Gibson J, Arthur C, To LB, Hughes TP,Raunow H. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. 2004 Int Med J 34;(3); 98-102 CIT 5
  172. Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D, Horvath N, Bardy P, Hui CH, Dart GW, To LB, Hughes TP. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. 2003Cytotherapy Vol 5, No 6, 534-541. CIT 2
  173. Branford S, Rudzki Z,Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. 2003 Leukemia, 17, 2401-2409 CIT 68
  174. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits thein vitro development of the onocyte/macrophage lineage from normal human bone marrow progenitors. 2003 Leukemia 17(9):1713-1721 CIT 35
  175. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Henslee ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM and Radich J. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. 2003 New England Journal of Medicine 349:1421-30 CIT 1174
  176. CH Hui, KY Goh, D White, S Branford, A Grigg, JF Seymour, YL Kwan, S Walsh, R Hoyt, A Trickett, B Rudzki, DDF Ma, LB To, TP Hughes. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. 2003 Leukemia 17:821-828.CIT 27
  177. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour J, Arthur C, Joske D, Lynch K, Hughes TP. The detection of BCR-ABL mutations in imatinib-treated CML patients is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. 2003 Blood 102: 276-283. CIT 356
  178. O’Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes TP, Lechner K, Nielsen J, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman J, Kantarjian, Taylor K, Verhoef G, Bolton A, Capdeville R, Druker B. Imatinib compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. 2003 New England Journal of Medicine 348: 994-1004. CIT 1517
  179. Borg M, Hughes TP, Horvath N, Rice M, Thomas AC. Renal toxicity after total body irradiation 2002 International Journal of Radiation Oncology Biology Physics 54(4): 1165-1173 CIT: 22
  180. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamemberane mutant V560Gkit is more sensitive to imatinib (STI571) compared to wild-type c-KIT whereas the kinase domain mutant D816Vkit is resistant. 2002 Molecular Cancer Therapeutics 1: 1115-1124. CIT 126
  181. Mullighan CG, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, Schwarer AP, Szer J, Tait BD, Bik To L, Bardy PG. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. 2002 Blood 99:3524-9 IF 10.9: CIT 129
  182. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High Frequency of Point Mutations Clustered Within the ATP Binding Region of BCR/ABL in CML and Ph-positive ALL Patients who Develop Imatinib (STI571) Resistance. 2002 Blood 99: 3472-3475 IF 10.9: CIT 413
  183. Branford S, Hughes TP, Rudzki Z. Proposed mechanism for transcription of both b2a2 and b3a2 BCR-ABL in chronic myeloid leukemia involving polymorphism within the BCR gene. 2002 British Journal of Haematology 117:875-877. CIT 11
  184. Lutwyche JK, Keough RA, Hughes TP, Gonda TJ. Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. 2001 British Journal of Haematology 114:632-634 CIT 6
  185. Hui CH, Bardy P, Hughes TP, Horvath N, To LB. Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. 2001 Clinics in Laboratory Haematology 23, 135-138 CIT 1
  186. Craddock C, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman J, Hughes TP, Derigs G. Engraftment of T-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. 2000 British Journal of Haematology 111, 797-800 CIT 16
  187. Szabo F, Horvath N, Seimon S, Hughes TP. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukaemia. 2000 Bone Marrow Transplant, 26:231-3 CIT 13
  188. Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. 2000 Br J Haematol, 109: 635-637. CIT 17
  189. Moore S, McDiarmid L, Hughes TP. Stem cell factor and chronic myeloid leukaemia. 2000 Leukaemia and Lymphoma 38:211-220 CIT 5
  190. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes TP, Herrmann R, Gibson J, Arthur C, Mathews J. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. 1999 Br J Haematol, 107: 409-18 CIT 44
  191. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. 1999 Br J Haematol 107: 587-599. CIT 112
  192. Moore S, Haylock DN, Levesque J-P, McDiarmid L, Samels L, To LB, Simmons PJ,Hughes TP. Stem cell factor as a single agent induces marked proliferation of the Philadelphia chromosome positive fraction of CML CD34+ cells. 1998 Blood 92: 2461-2470 CIT 27
  193. Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP. Establishment of a reproducible model of chronic phase chronic myeloid leukemia in NOD/SCID mice using blood derived mononuclear or CD34 positive cells. 1998 Blood 91: 630-640. CIT 45
  194. Iverson PO, Lewis ID, Turczynowicz S, Hasle H, Niemeyer C, Schmiegelow K, Bastiras S, Biondi A, Hughes TP, Lopez AF A second generation GM-CSF analogue that prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice.1997 Blood 90: 4910-4917 CIT 31
  195. White DL, Hutchins CJ, Turczynowicz S, Suttle J, Haylock DN, Hughes TP, Juttner CA, To LB Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH. 1997 Pathology 29: 289-293. CIT 7
  196. Lewis ID, Haylock DN, Moore S, To LB, Hughes TP. Peripheral blood is a source of BCR-ABL negative pre-progenitors in early chronic phase chronic myeloid leukemia.1997 Leukemia 11:581-587. CIT 7
  197. Hughes TP, Grigg A, Szer J, Ho J, Dale BM, Green RM, Norman JE, Sage RE, Herrmann R, Cannell P, Schwarer AP, Taylor K, Atkinson K, Arthur C. Mobilisation of predominantly Philadelphia chromosome-negative progenitors using cyclophosphamide and rHu G-CSF in early chronic phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.1997 Br J Haematol 96: 635-640. CIT 12
  198. Lewis ID, Haylock DN, Moore S, To LB, Juttner CA, Hughes TP. Identification of normal primitive progenitors in blood and mobilised blood in chronic myeloid leukaemia. 1995. Blood 86(10):2085-2085. CIT 1
  199. White DL, Hutchins CJ, Haylock DN, Turczynowicz S, Bishop A, To LB, Hughes TP, Juttner CA. Direct analysis of FACS sorted hemopoietic cell fractions using FISH.1995 Biotechniques 18: 818-821. CIT 3
  200. Kumar S, White DL, Takai S, Turczynowicz S, Juttner C, Hughes TP Apoptosis regulatory gene NEDD2 maps to human chromosome 7q34-35, a region frequently affected in haematological neoplasms. 1995. Human Genet 95: 641-644. CIT 21
  201. Orr SL, Hughes TP, Sawyers CL, Kato RM, Quan SG, Williams SP, Witte ON, Hood LE. Characterization of human bone marrow cDNAs by differential screening, expression and partial sequence determination. 1994 Proc Natl Acad Sci USA 91:11869-11873. CIT 12
  202. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. 1993 Blood 82: 1929-1934CIT 340
  203. Marks DI, Cullis JO, Ward K, Lacey S, Szydlo R, Hughes TP, Schwarer AP, Mackinnon S, Barrett AJ, Hows JM, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. 1993 Ann Int Med 119: 207-211. CIT 184
  204. Cross NCP, Hughes TP, Lin F, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. 1993 Br J Haematol 84: 67-74 CIT 173
  205. Cullis JO, Szydlo RM, Cross NC, Marks DI, Schwarer AP, Hughes TP, Mackinnon S, Hale G, Waldmann H, Hows JM, Goldman JM Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex-vivo and in vivo T-cell depletion. 1993 Bone Marrow Transplant 11: 107-111. CIT 10
  206. Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP, Mackinnon S, Apperley J, Barret J, Hows JM, Goldman JM HLA-identical sibling donor marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. 1992 Br J Haematol 81: 383-390. CIT 42
  207. Cullis JO, Schwarer AP, Hughes TP, Hows JM, Franklin I, Morgenstern G, Goldman JM. Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for reconditioning. 1992 Br J Haematol 80: 33-39. CIT 41
  208. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. 1992 Blood 79: 1379-1381. CIT 144
  209. Sucai Bi, Hughes TP, Bungey J, Chase A, de Fabritiis P, Goldman JM. P 53 in chronic myeloid leukemia cell lines. 1992 Leukemia 6: 839-842. CIT 3
  210. Hughes TP, Ambrosetti A, Barbu V, Bartram C, Battista R, Biondi A, Chiamenti A, Cimino G, Ernst P, Frassoni F, Gasparini G, Gentilini A, Gluckman E, Grosveld G, Guerrasio A, Hegewich S, Janssen JWG, Keating A, Lo Coco F, Martiat P, Martinelli G, Mills K, Morgan G, Nadali G, Pelicci PG, Perona P, Pignatti PF, Richard P, Saglio G, Trabetti M, Turco A, Veneri D, Zaccaria A, Zander A, Goldman JM. 1991 Report of the third workshop of the molecular biology/BMT study group. Leukemia 5: 448-451 CIT 23
  211. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukaemia after bone marrow transplantation for chronic myeloid leukaemia: role of PCR in predicting relapse. 1991. Blood 77: 874-878 CIT 241
  212. Hughes TP, Goldman JM. Improved results with PCR for CML (letter). 1990 Lancet 336:812 CIT 18
  213. Hughes TP, Janssen JWG, Morgan G, Martiat P, saglio G, Pignon JM, Pignatti FP, Mills K, Keating A Gluckman E, Bartram CR, Goldman JM. False positive results with PCR to detect leukaemia-specific transcript (letter) 1990 Lancet 335:1037-1038 CIT 46
  214. Morgan GJ, Hernandez A, Chan LC, Hughes TP, Martiat P, Wiedemann LM. The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. 1990 British Journal of Haematology 76: 33-38. CIT 48
  215. Kaminski E, Hows J, Man S, Brooks P, Mackinnon S, Hughes TP, Avakian O, Goldman JM, Batchelor JR. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. 1990Transplantation 48: 608-613. CIT 176
  216. Mackinnon S, Hows JM, Goldman JM, Arthur CK, Hughes TP, Apperley JF, Jones L, Batchelor JR, Brookes P, Catovsky D, Galton DAG, Bidwell J, Bradley B, Cleaver S, Hale G, Waldmann H. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated donors. 1990 Experimental Hematology 18: 421-425. CIT 48
  217. Hughes TP, Martiat P, Morgan G, Sawyers C, Witte ON, Goldman JM. Significance of residual leukaemia transcripts after bone marrow transplant for CML (letter) 1990Lancet 335:50
  218. Hughes TP & Goldman JM. Biological importance of residual leukaemic cells after BMT for CML: can the polymerase chain reaction help? 1990 Bone Marrow Transplantation 5:3-6. CIT 32
  219. Kaminski E, Hows J, Brookes P, Mackinnon S, Hughes TP, Ovakian O, Goldman J, Batchelor JR. Alloreactive cytotoxic T-cell frequency analysis and HLA matching for bone marrow transplants from HLA matched unrelated donors. 1989Transplantation Proceedings 21: 2976-2981. CIT 6
  220. Morgan GJ, Hughes TP, Janssen JWG, Gow J, Guo AP, Goldman JM, Wiedemann LM, Bartram C. Polymerase chain reaction for the detection of residual leukaemia.1989 Lancet 1: 928-929. CIT 161
  221. Hughes TP, Jones P, Rozenberg MC. Hypergammaglobulinemia and the asnticardiolipin antibody test (letter) 1989 Arthritis and Rheumatism 32:813
  222. Hughes TP, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. 1989 British Journal of Haematology 73: 462-467. CIT 37
  223. Books, Chapters

  224. Hughes, TP and Goldman, JM. Chronic Myeloid Leukemia. 1994 In: Hematology: Basic Principles and Practices. Hoffman, Benz, Shattil, Furie, Cohen (Eds.) NY: Churchill Livingstone, pp. 854-869.
  225. Hui CH, Hughes TP Strategies for the treatment of imatinib-resistant chronic myeloid leukaemia. 2003 Clinical Advances in Hematology and Oncology 1:538-545
  226. Hughes TP. Molecular monitoring in chronic myeloid leukemia in Hematology2003 American Society of Hematology Education Program Book.
  227. Ross DM, Hughes TP. (2004) Cancer treatment with kinase inhibitors: what have we learnt from imatinib? British Journal of Cancer 90(1):12-9 CIT 24
  228. Faderl S, Hochhaus A, Hughes TP (2004) Monitoring of minimal residual disease in CML North American Clinics in Hematology and Oncology 18(3):657-70. CIT 6
  229. Hochhaus A, Hughes TP (2004) Clinical resistance to imatinib: mechanisms and implications. North American Clinics in Hematology and Oncology 18(3)641-56.CIT 50
  230. Ross DM, Hughes TP. (2004) Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer:90(1):12-19 CIT 25
  231. Hughes TP, Branford S. Molecular monitoring of CML. Semin Haematol 40 No: 2 (suppl 2) 62-68. CIT 46
  232. Hughes TP. Comments on the Hammersmith Policy Semin Haematol 40, No 2 (suppl 2) 111-112
  233. Hughes TP. ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring. ASH Education Program Book. 2006: 211-218
  234. Branford S, Hughes TP. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med. 2006 1125: 93-106
  235. Branford S, Hughes TP. Diagnosis and monitoring of chronic myeloid leukaemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006 125: 69-92 CIT 1
  236. Hurst N, Hughes TP, Branford S. Monitoring CML: State of the art. In: Cortes J Deininger M eds. Chronic Myelogenous Leukaemia. 2006
  237. Hughes TP, Branford S. Monitoring Disease Response. In: Melo JV, Goldman J Meds. Myeloproliferative disorders. Haematologic Malignancies. Berlin: Springer-Verlag. 2007 143-164
  238. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. 2009 ASH Education Program (1) 477-787 CIT 66
  239. Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology American Society of Hematology Education Program. 2013;2013:168-175. CIT 24
  240. Hughes TP, Ross D, Melo J: Handbook of Chronic Myeloid Leukemia. Springer International Publishing 2014
  241. Ross DM, Hughes TP. Discontinuation of Therapy and Treatment-Free Remission in CML. Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. 2016 183-193 Springer Japan.
  242. Yeung DT, Hughes TP, Chronic Myeloid Leukemia. In: Hoffbrand AV, Higgs DR, Keeling DM and Mehta AB eds. Postgraduate Haematology 7th Edition. Oxford, UK: John Wiley & Sons. 2016 419-437.
Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.